These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33951531)

  • 1. Lipid Optimization in Lower Extremity Peripheral Arterial Disease.
    Sucharitkul PPJ; Jones KL; Scott DJA; Bailey MA
    Ann Vasc Surg; 2021 Oct; 76():542-554. PubMed ID: 33951531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
    Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
    Reynolds TM; Pottle A; Quoraishi SH
    Vasc Health Risk Manag; 2021; 17():227-237. PubMed ID: 34054297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease.
    Annex BH; Cooke JP
    Circ Res; 2021 Jun; 128(12):1944-1957. PubMed ID: 34110899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The challenge of peripheral arterial disease: How do we improve outcome?
    Stock JK
    Atherosclerosis; 2018 Mar; 270():196-198. PubMed ID: 29395100
    [No Abstract]   [Full Text] [Related]  

  • 8. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease.
    Lee JH; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2016 Mar; 63(3):756-63. PubMed ID: 26603545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?
    Rymer JA; Swaminathan RV; Aday AW; Patel MR; Gutierrez JA
    Curr Cardiol Rep; 2021 Jan; 23(3):13. PubMed ID: 33483872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty.
    Wolf S; Spirk D; Forgo G; Sebastian T; Voci D; Kucher N; Barco S
    Vasa; 2022 Nov; 51(6):357-364. PubMed ID: 36052607
    [No Abstract]   [Full Text] [Related]  

  • 12. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia and peripheral arterial disease.
    Yadav A; Sawant V; Singh Bedi V; Yadav K
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S86-S89. PubMed ID: 38224837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
    Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
    J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications for REDUCE IT in clinical practice.
    Bittner V
    Prog Cardiovasc Dis; 2019; 62(5):395-400. PubMed ID: 31715195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.